NIPT

China Non-Invasive Prenatal Testing (NIPT) Market to Surge to $1,083 Million by 2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Health, Consumer, Baby, Maternity, General Health, Pharmaceutical, Biotechnology, NIPT, Growth, Dietary supplement

The "China Non-Invasive Prenatal Testing Market Growth, Share, Size, Trends and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Non-Invasive Prenatal Testing Market Growth, Share, Size, Trends and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering.
  • The report offers an exhaustively researched overview of the Chinese non-invasive prenatal testing market with up-to-date data on the current market landscape and a forecast that stretches to 2032.
  • A detailed overview of the critical factors driving the expansion of the China non-invasive prenatal testing market is included in the report.
  • What is the total market size and forecast (until 2032) for the China non-invasive prenatal testing market?

Igentify Launches New NIPT and Pharmacogenomics Offerings

Retrieved on: 
Tuesday, March 5, 2024
Technology, Science, Family, Genetics, Consumer, Clinical Trials, Biotechnology, Health, Health Technology, Apps, Applications, Research, Software, Other Health, Internet, Parenting, Pharmaceutical, Baby, Maternity, ACOG, NIPT, ECS, Workflow

Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.

Key Points: 
  • Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.
  • This new roll-out comes in addition to their Expanded Carrier Screening (ECS) offering.
  • The NIPT workflow includes a patient web-app that facilitates all aspects of patient intake, including an ACOG-compliant consenting process using Igentify’s proprietary video technology to create highly personalized educational videos for each patient.
  • “We are thrilled to expand the accessibility of our platform with programs focused on non-invasive prenatal testing and pharmacogenomics,” said Elliott Greenspan, Chief Innovation Officer and Co-founder of Igentify.

Molecular Diagnostics in Oncology, Genetic/Inherited Diseases and NIPT 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 29, 2024
Health, Oncology, ISH, NGS, DSM-IV codes, Research, Molecular diagnostics, IVD, Knowledge, NIPT, Cancer, Woman, Medicine, Risk, FISH, Recurrence, Laboratory, FDA, Biomarker, Diagnosis, PCR, Inherit, Segment, Chromosome, Gene expression, Medical imaging

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the fields of rare inherited/ genetic diseases and NIPT have become areas of new breakthroughs in healthcare.
  • These and other technologies and applications in oncology, rare inherited/ genetic disease, and NIPT molecular diagnostic testing are covered in the report.
  • The report contains detailed market data on the following IVD segments for their use in molecular testing:
    Molecular Diagnostics in Oncology Market by Segment, 2023-2028

Identifai-Genetics Launches Its First U.S. Clinical Trial, Led by Professor Ronald Wapner

Retrieved on: 
Thursday, January 11, 2024
Woman, Columbia, Assistant, Associate, DNA, Gynaecology, Birth, NIPT, Partnership, AI, Genetics, TEL, Pregnancy, Disease, Genetic counseling, Prevalence, Columbia University, Obstetrics, Anomaly, Parent, Clinical trial, Research, Fetus, Trial of the century

Identifai's platform and diagnostic tools enable early detection of the whole spectrum of fetal genetic disorders in an accessible, cost-effective and risk-free manner.

Key Points: 
  • Identifai's platform and diagnostic tools enable early detection of the whole spectrum of fetal genetic disorders in an accessible, cost-effective and risk-free manner.
  • Identifai's US clinical study is aimed at demonstrating the performance and effectiveness of the company's novel technology in real-world scenarios within the United States.
  • The principal investigator in the study is world-renowned Professor Ronald J. Wapner, Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Columbia University Irving Medical Center.
  • This study marks a critical milestone in transforming Identifai's technology into a clinical offering accessible to millions of women in the US and across the globe".

Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend

Retrieved on: 
Monday, January 8, 2024
Pseudogene, RNA, Biomedical Research, Protein, NIPT, Antibody, Telecommunications, Workflow, Research, DNA, SAN, Methylation, Biomarker, Infection, BioLegend, Fine chemical

This marks the first instance of an early access version of RAPTOR with Pleno’s groundbreaking multi-omic readout technology called Hypercoding ™ verified outside of its development lab.

Key Points: 
  • This marks the first instance of an early access version of RAPTOR with Pleno’s groundbreaking multi-omic readout technology called Hypercoding ™ verified outside of its development lab.
  • The RAPTOR instrument platform utilizes Hypercoding to detect these biomarkers rapidly and efficiently at a sample throughput that is scalable from a couple dozen samples to 96.
  • To this end, Pleno and BioLegend have collaborated to integrate their technologies, facilitating a streamlined approach for customers to enable multi-omic content.
  • “We are extremely proud to see the first of our RAPTOR instruments leave the nest,” said Pieter van Rooyen, founder and CEO of Pleno.

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, December 27, 2023
Class Action Lawsuit, Professional Services, Legal, Telephone, NTRA, Marketing, Panorama, NIPT, DSM-IV codes, FDA, Complaint, News, Fetus, Communication, Campaign, Insurance, P.C, The New York Times, Oportunidades, Chromosome, Genetic testing, Growth, Hindenburg Research, Patient, Safety, Cryptocurrency

Our investigation concerns whether the board of directors of Natera have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Natera have breached their fiduciary duties to the company.
  • Natera, a Delaware corporation with principal executive offices in Austin, Texas, offers genetic testing in the areas of women’s health, oncology, and organ health.
  • Among other things, The New York Times reported that Natera’s positive results for several genetic disorders were incorrect more than 80 percent of the time.
  • In addition, the FDA advised health care providers that they should not rely on NIPT results alone to diagnose chromosomal abnormalities or disorders.

Yourgene Health and Laboriad Launch Non-invasive Prenatal Testing in Morocco

Retrieved on: 
Thursday, November 9, 2023
Research, Medical Devices, Women, Hospitals, Genetics, Health Technology, Biotechnology, Consumer, Health, Science, Laboratory, Pregnancy, NIPT, Failure, Novacyt, Risk, Partnership, IONA, Workflow, Fetus, Anxiety, Parent, Dietary supplement, Birth control

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, has installed the first non-invasive prenatal testing (NIPT) workflow in Morocco based on the IONA® test at the Centre de Biologie Riad (Laboriad).

Key Points: 
  • Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, has installed the first non-invasive prenatal testing (NIPT) workflow in Morocco based on the IONA® test at the Centre de Biologie Riad (Laboriad).
  • The analysis is performed on a maternal blood sample, using next-generation sequencing technology, with test results available in three days.
  • Blood samples taken in Morocco are typically sent to countries such as France and Germany for NIPT.
  • Lyn Rees, Executive Director, Yourgene Health, said: “Yourgene is committed to delivering best-in-class NIPT solutions and continues to be a leading player in the global NIPT market and a trusted provider.

BillionToOne Announces Clinical Outcomes Data for UNITY Fetal Risk™ Screen, Demonstrating Exceptional Accuracy in General Pregnancy Population

Retrieved on: 
Monday, October 30, 2023
Child, Prenatal care, Sickle cell disease, Test management, Doctor of Philosophy, NIPT, Research, Male, Cystic fibrosis, Risk, Workflow, Fetus, Alpha, NPV, Patient, Dietary supplement

MENLO PARK, Calif., Oct. 30, 2023 /PRNewswire/ -- BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today that a peer-reviewed research study of the UNITY Fetal Risk Screen has been published in Prenatal Diagnosis. The study demonstrates that the test accurately provides direct fetal insights into prevalent autosomal recessive conditions such as Cystic Fibrosis, Spinal Muscular Atrophy, and Alpha and Beta Hemoglobinopathies (including Sickle Cell Disease). "Given this high accuracy and an NPV of 99.8%, this workflow should be considered as an option for most of the general pregnant population." the study's authors concluded.

Key Points: 
  • "Given this high accuracy and an NPV of 99.8%, this workflow should be considered as an option for most of the general pregnant population."
  • "The data not only corroborates previous results but also expands upon them by including a wider population of the general pregnant population," said Oguzhan Atay, PhD, and CEO of BillionToOne.
  • "This study provides strong evidence that the UNITY Fetal Risk Screen is primed to be the new standard in prenatal care."
  • A total of 528 clinical newborn outcomes for positive carrier pregnancies were collected, with at least 75 outcomes per condition.

Global Non-Invasive Prenatal Testing (NIPT) Market Analysis Report 2023: A $9.37 Billion Market by 2028 - Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health, Medical Devices, Trisomy, Laboratory, Insurance, Plasma, DSM-IV codes, Prenatal care, Incidence, Pregnancy, Diagnosis, Prevalence, NIPT, Research, Entrepreneurship, ELISA, Chromosome, Mother, Point-of-care testing, NGS, Ecosystem, Hospital, Overalls, Safety, Investment, Patient, Parent, DNA, Dietary supplement, Medical imaging, Pharmaceutical industry, Medical device, Growth

The "Non-Invasive Prenatal Testing (NIPT) Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Invasive Prenatal Testing (NIPT) Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The global NIPT market is experiencing substantial growth, partly attributed to expanded insurance coverage and reimbursement policies worldwide.
  • The dominance of the high- and average-risk segments in the global Non-invasive Prenatal Testing (NIPT) market is due to their specific needs.
  • Diagnostic centers experience significant growth in the global Non-invasive Prenatal Testing (NIPT) market due to their specialized expertise and equipment.

Olive Fertility Centre Nurse Educator Acknowledged at Canadian Fertility and Andrology Society (CFAS) 2023 Meeting

Retrieved on: 
Monday, September 25, 2023
Olive, Test management, Reproductive medicine, University, Professional, LGBTQ2, Woman, Medicine, Research, Mentorship, Multimedia, BSN, IVF, Fertility, Patient, International Union of Immunological Societies, Nursing, Entrepreneurship, NIPT, Hospital

VANCOUVER, BC, Sept. 25, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is delighted to announce that Paula Anderson, BSN, Nurse Educator at Olive Fertility Centre Vancouver, has been honoured with the prestigious Carole Rheaume Award at the Canadian Fertility and Andrology Society (CFAS) 2023 Meeting. This award serves as a recognition of her dedication and exceptional work in the field of reproductive medicine.

Key Points: 
  • Paula Anderson, BSN, Nurse Educator at Olive Fertility Centre Vancouver, has been honoured with the prestigious Carole Rheaume Award at the Canadian Fertility and Andrology Society (CFAS) 2023 Meeting.
  • VANCOUVER, BC, Sept. 25, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is delighted to announce that Paula Anderson, BSN, Nurse Educator at Olive Fertility Centre Vancouver, has been honoured with the prestigious Carole Rheaume Award at the Canadian Fertility and Andrology Society (CFAS) 2023 Meeting.
  • The Canadian Fertility and Andrology Society (CFAS) is Canada's premier national organization of professionals specializing in reproductive medicine.
  • She has become a passionate educator at Olive Fertility Centre, nurturing and mentoring the new generations of fertility nurses.